Simulations Plus, Inc. (AMEX: SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development, announced that it has released a unique new predictive capability as part of its new ADMET Predictor™ Version 2.3.

Dr. Michael Bolger, chief scientist for Simulations Plus, said: “One of the FDA-required tests for any new drug is for the potential to cause mutations in the DNA of various strains of salmonella. Salmonella is not just a single bacterial form; rather, there are thousands of different strains. In the past, we and others have built our predictive software models on data sets where the mutagenicity data were pooled for all strains. Simulations Plus’ new predictive capability is not just one model, but a series of models based on data for ten different strains of salmonella. After months of work, we’ve developed a capability for predicting whether a particular new drug-like molecule is likely to cause mutations in any one of these strains. The overall predictive accuracy is improved with this approach over models built on pooled data for different strains.”

Walt Woltosz, chairman and chief executive officer of Simulations Plus, added: “Our ability to create these new software models comes from a database we acquired as part of our Bioreason asset acquisition in November 2005. One of the many assets we acquired was a proprietary database of over 5,000 compounds with specific data for mutagenicity for ten different strains of salmonella that had been developed by scientists at Bioreason. We believe this mutagenicity database which we now own is unique, and that our new predictive capability is also unique, further enhancing our best-in-class structure-to-property prediction software, ADMET Predictor.”